Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of ATRAGEN in Relapsed/Refractory Hodgkin's Disease
NCT00005969Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 1999
- Primary completion
- Jan 2001
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
A Phase 2 trial of liposomal tretinoin in Hodgkin lymphoma (HL), sponsored by University of Texas MD Anderson Cancer Center. Planned start Sep 1999; status: withdrawn.
02
Drugs
liposomal tretinoin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00005969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005969.